Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Soundos Moualla

Interventional Cardiology Prescott, AZ Medical Doctor

NPI 1396853461 CMS profile 335470

1001 Willow Creek Rd Ste 2200, 1001 Willow Creek Road Suite 2200, Prescott, AZ 86301

Open in the dashboard

General payments

$36,060

383 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Soundos Moualla of Prescott, AZ is reported in the CMS Open Payments database as having received $36,060 across 383 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,756 68
2024 General $16,284 85
2023 General $1,700 50
2022 General $2,008 49
2021 General $4,759 41
2020 General $477 13
2019 General $9,078 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Soundos Moualla
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Soundos Moualla were reported at $1,756. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Soundos Moualla Interventional Cardiology median Middle half National median
2019 $9,078 $1,097 $329–$3,048 $163
2020 $477 $473 $161–$1,480 $114
2021 $4,759 $677 $233–$1,827 $132
2022 $2,008 $978 $333–$2,724 $149
2023 $1,700 $1,136 $382–$2,986 $160
2024 $16,284 $1,181 $395–$3,326 $164
2025 $1,756 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $15,828 69 payments
  2. Edwards Lifesciences Corporation $14,450 209 payments
  3. Medtronic Vascular, Inc. $1,876 19 payments
  4. Abiomed $1,623 12 payments
  5. Boston Scientific Corporation $585 10 payments
  6. Medtronic, Inc. $584 10 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $269 11 payments
  8. Cardiovascular Systems Inc. $123 3 payments
  9. Novartis Pharmaceuticals Corporation $102 5 payments
  10. Janssen Pharmaceuticals, Inc $94 6 payments
  11. Other $525 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,604 353 payments
  2. Consulting Fee $12,338 3 payments
  3. Travel and Lodging $8,619 26 payments
  4. Honoraria $2,500 1 payment
Products named General payments · program years 2019–2025
  1. MITRACLIP Vascular $11,822 12 payments
  2. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $2,728 52 payments
  3. CoreValve Evolut $1,660 7 payments
  4. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $1,626 59 payments
  5. Impella $1,480 9 payments
  6. SAPIEN 3 Ultra RESILIA $974 59 payments
  7. MITRACLIP Vascular $958 13 payments
  8. MITRACLIP Structural Heart $452 5 payments
  9. Mitra Clip system $416 7 payments
  10. COREVALVE EVOLUT R $306 3 payments
  11. Other $4,109 118 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

4,308

Median for Interventional Cardiology: 2,236

Drug cost

$654,311

Median for Interventional Cardiology: $380,412

Branded share of claims

25.9%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 269 $349,119
Entresto Sacubitril/Valsartan Brand 67 $95,950
Brilinta Ticagrelor Brand 45 $43,982
Repatha Sureclick Evolocumab Brand 28 $39,161
Xarelto Rivaroxaban Brand 15 $23,092
Jardiance Empagliflozin Brand 16 $21,972
Farxiga Dapagliflozin Propanediol Brand 20 $21,660
Ranolazine Er Ranolazine Brand 51 $5,832
Clopidogrel Clopidogrel Bisulfate Brand 395 $5,162
Atorvastatin Calcium Generic 396 $3,859

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$192,160

Medicare's payments for the services billed

Medicare patients

494

Average age 77

Services billed

1,666

211 women, 283 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 45%
Heart failure 43%
Atrial fibrillation 42%
Chronic kidney disease 36%
Diabetes 30%
COPD 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

383 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record